392 related articles for article (PubMed ID: 29451881)
1. Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.
Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Melak B; Chanyalew M; Tadesse Z; Callahan EK; Nash SD
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006270. PubMed ID: 29451881
[TBL] [Abstract][Full Text] [Related]
2. Coverage, social mobilization and challenges of mass Zithromax administration campaign in South and South East zones of Tigray, Northern Ethiopia: A cross sectional study.
Mulugeta A; Gebregergs GB; Asfaw S; Yemane D; Mitiku M; Meresa B; Gigar G; Kidane A
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006288. PubMed ID: 29481558
[TBL] [Abstract][Full Text] [Related]
3. Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia.
Ebert CD; Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Ayele Z; Melak B; Chanyalew M; Gashaw B; Tadesse Z; Callahan EK; Jenness SM; Nash SD
Trop Med Int Health; 2019 Apr; 24(4):493-501. PubMed ID: 30674087
[TBL] [Abstract][Full Text] [Related]
4. Coverage assessment survey following trachoma mass drug administration (MDA) in six districts of Oromia, Western Ethiopia, 2017.
Bekuma TT; Mosisa Kebebew G; Desalegn Waktole Z; Markos Cafo J; Wirtu D; Gaddisa S
PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007924. PubMed ID: 31841516
[TBL] [Abstract][Full Text] [Related]
5. Self-Reported Side Effects following Mass Administration of Azithromycin to Eliminate Trachoma in Amhara, Ethiopia: Results from a Region-Wide Population-Based Survey.
Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Chanyalew M; Melak B; Ayele Z; Gessese D; Ayenew G; Gashaw B; Tadesse Z; Callahan EK; Nash SD
Am J Trop Med Hyg; 2019 Mar; 100(3):696-699. PubMed ID: 30675840
[TBL] [Abstract][Full Text] [Related]
6. Trachoma prevalence remains below threshold in five districts after stopping mass drug administration: results of five surveillance surveys within a hyperendemic setting in Amhara, Ethiopia.
Nash SD; Stewart AEP; Astale T; Sata E; Zerihun M; Gessese D; Melak B; Ayenew G; Ayele Z; Bayissasse B; Chanyalew M; Tadesse Z; Callahan EK
Trans R Soc Trop Med Hyg; 2018 Dec; 112(12):538-545. PubMed ID: 30265355
[TBL] [Abstract][Full Text] [Related]
7. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
King JD; Teferi T; Cromwell EA; Zerihun M; Ngondi JM; Damte M; Ayalew F; Tadesse Z; Gebre T; Mulualem A; Karie A; Melak B; Adugna M; Gessesse D; Worku A; Endashaw T; Admassu Ayele F; Stoller NE; King MR; Mosher AW; Gebregzabher T; Haileysus G; Odermatt P; Utzinger J; Emerson PM
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2732. PubMed ID: 24625539
[TBL] [Abstract][Full Text] [Related]
9. Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study.
Tilahun Z; Fenta TG
BMC Ophthalmol; 2018 Aug; 18(1):193. PubMed ID: 30081851
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Ocular Chlamydia trachomatis Infection in Amhara Region, Ethiopia, after 8 Years of Trachoma Control Interventions.
Nash SD; Chernet A; Weiss P; Nute AW; Zerihun M; Sata E; Gessese D; Jensen KA; Ayele Z; Melak B; Zeru T; Mengistu A; Abebe A; Seife F; Tadesse Z; Callahan EK
Am J Trop Med Hyg; 2023 Feb; 108(2):261-267. PubMed ID: 36623484
[TBL] [Abstract][Full Text] [Related]
11. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
[TBL] [Abstract][Full Text] [Related]
12. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
[TBL] [Abstract][Full Text] [Related]
13. Stopping azithromycin mass drug administration for trachoma: A systematic review.
Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
[TBL] [Abstract][Full Text] [Related]
14. The population-based prevalence of trachomatous scarring in a trachoma hyperendemic setting: results from 152 impact surveys in Amhara, Ethiopia.
Astale T; Ebert CD; Nute AW; Zerihun M; Gessese D; Melak B; Sata E; Ayele Z; Ayenew G; Callahan EK; Haile M; Zeru T; Tadesse Z; Nash SD
BMC Ophthalmol; 2021 May; 21(1):213. PubMed ID: 33985443
[TBL] [Abstract][Full Text] [Related]
15. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
[TBL] [Abstract][Full Text] [Related]
16. Integrating an NTD with one of "The big three": combined malaria and trachoma survey in Amhara Region of Ethiopia.
Emerson PM; Ngondi J; Biru E; Graves PM; Ejigsemahu Y; Gebre T; Endeshaw T; Genet A; Mosher AW; Zerihun M; Messele A; Richards FO
PLoS Negl Trop Dis; 2008 Mar; 2(3):e197. PubMed ID: 18350115
[TBL] [Abstract][Full Text] [Related]
17. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands.
Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC
Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658
[TBL] [Abstract][Full Text] [Related]
18. Mass drug administration for trachoma: how long is not long enough?
Jimenez V; Gelderblom HC; Mann Flueckiger R; Emerson PM; Haddad D
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003610. PubMed ID: 25799168
[TBL] [Abstract][Full Text] [Related]
19. Serology for trachoma surveillance after cessation of mass drug administration.
Martin DL; Bid R; Sandi F; Goodhew EB; Massae PA; Lasway A; Philippin H; Makupa W; Molina S; Holland MJ; Mabey DC; Drakeley C; Lammie PJ; Solomon AW
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
[TBL] [Abstract][Full Text] [Related]
20. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
